- Morgan Stanley Global Healthcare Conference, New York City, September 9, 2013, 10:35 a.m. ET
- Stifel Healthcare Conference 2013, Boston, September 11, 2013, 9:45 a.m. ET
Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate
Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.